Program Indication Research Preclinical Phase 1 Phase 2 Phase 3
Pulmonary Sarcoidosis


Other ILDs (CTD-ILD; CHP)(1)


Healthy Japanese Volunteers(2)


ATYR2810 Solid Tumors


NRP2 mAbs Cancer; Inflammation


AARS-1; DARS‑1(3) Cancer; Fibrosis; Inflammation


Program Target Phase
Efzofitimod (ATYR1923) Pulmonary Sarcoidosis Phase 2
Other ILDs (CTD-ILD; CHP)1 Phase 1
Healthy Japanese Volunteers2 Phase 1
ATYR2810 Solid Tumors Preclinical
NRP2 mAbs Cancer; Inflammation Research
AARS-1; DARS-1(3) Cancer; Fibrosis; Inflammation Research

(1) CTD-ILD: connective tissue disease-related ILD (e.g. Scleroderma-related ILD); CHP: chronic hypersensitivity pneumonitis
(2) In partnership with Kyorin Pharmaceutical Co., Ltd. Kyorin’s Phase 1 study in healthy Japanese volunteers has been completed. Kyorin is eligible to participate in future efzofitimod trials sponsored by aTyr.
(3) The next two candidates from our tRNA synthetase platform; initial focus on NK cell biology.